Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)

Sponsor
University of Luebeck
Study ID
NCT01638858
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lucentis (Ranibizumab) — DRUG
    Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry

Study Details

In this prospective, open-label clinical study is to investigate the behavior of the retinal functions during development of diabetic macular disease (DME) under the influence of Lucentis. Measurements with the multifocal electroretinogram (ERG) and microperimetry is used here as an objective criteria to information about the retinal function obtain.

Key Dates

First listed
Jul 12, 2012
Start date
Oct 31, 2011
Status verified
Jul 2014
Primary completion
Jul 31, 2014

Study Design

Enrollment
25 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Lucentis (Ranibizumab)

Primary Outcome Measure

Main outcome measures are the changes of retinal function of the macula monitored by multifocal-ERG as measured 12 months [ Time Frame: 12 months ]

Related Studies